Hengrui Medicine gains approval for two innovative drugs

Jiangsu Hengrui Medicine (SSE:600276) announced it has received conditional approval from the National Medical Products Administration for its Class 1 innovative drug, apple acid famitinib capsules, in conjunction with its injection of camrelizumab, for the treatment of recurrent or metastatic cervical cancer patients who have failed previous platinum-containing chemotherapy but have not received bevacizumab treatment. In addition, the company's camrelizumab injection has been approved for a total of nine indications in China.